stoxline Quote Chart Rank Option Currency Glossary
  
Viking Therapeutics, Inc. (VKTX)
25.965  -0.315 (-1.2%)    06-20 11:34
Open: 26.3
High: 26.59
Volume: 1,077,782
  
Pre. Close: 26.28
Low: 25.56
Market Cap: 2,916(M)
Technical analysis
2025-06-20 11:20:53 AM
Short term     
Mid term     
Targets 6-month :  33.16 1-year :  35.2
Resists First :  28.39 Second :  30.13
Pivot price 27.13
Supports First :  25.55 Second :  21.26
MAs MA(5) :  26.28 MA(20) :  27.21
MA(100) :  27.77 MA(250) :  44.3
MACD MACD :  -0.2 Signal :  0
%K %D K(14,3) :  11.9 D(3) :  17.4
RSI RSI(14): 42.6
52-week High :  81.73 Low :  18.92
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ VKTX ] has closed above bottom band by 14.9%. Bollinger Bands are 32.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 26.9 - 27.05 27.05 - 27.22
Low: 25.38 - 25.55 25.55 - 25.73
Close: 25.96 - 26.26 26.26 - 26.57
Company Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Headline News

Mon, 16 Jun 2025
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Yahoo Finance

Mon, 16 Jun 2025
Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200% - TipRanks

Thu, 12 Jun 2025
Viking Therapeutics (VKTX) Rises on Expected Developments - MSN

Thu, 12 Jun 2025
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance

Tue, 03 Jun 2025
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

Fri, 30 May 2025
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 112 (M)
Shares Float 110 (M)
Held by Insiders 2.1 (%)
Held by Institutions 70 (%)
Shares Short 25,540 (K)
Shares Short P.Month 25,460 (K)
Stock Financials
EPS -1.16
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.53
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -11.8 %
Return on Equity (ttm) -14.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -134 (M)
Levered Free Cash Flow -98 (M)
Stock Valuations
PE Ratio -22.15
PEG Ratio 0
Price to Book value 3.4
Price to Sales 0
Price to Cash Flow -21.54
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android